Coherus Oncology (CHRS) Cash & Equivalents (2013 - 2026)

Coherus Oncology has reported Cash & Equivalents for 14 years, with the latest figure at $115.2 million in Q1 2026.

• Quarterly Cash & Equivalents rose 39.83% year-over-year to $115.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $115.2 million (up 39.83% YoY) and the FY2025 annual result came in at $88.9 million, down 29.45% from the prior year.
• Cash & Equivalents advanced to $115.2 million in Q1 2026 per CHRS's latest filing, from $88.9 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $325.7 million in Q1 2022 and troughed at $16.1 million in Q1 2023.
• A 5-year average of $145.5 million and a median of $103.4 million in 2025 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents plunged 95.04% in 2023, then jumped 1509.01% in 2024.
• Over 5 years, Cash & Equivalents stood at $63.5 million in 2022, then soared by 61.91% to $102.9 million in 2023, then gained by 22.45% to $126.0 million in 2024, then declined by 29.45% to $88.9 million in 2025, then grew by 29.66% to $115.2 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $115.2 million, $88.9 million, and $103.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.